INTRODUCTION {#s1}
============

Lung cancer is the leading cause of cancer-related death, accounting for more than 27% of all cancer deaths worldwide \[[@R1]\]. Lung cancer is classified as non-small cell lung cancer (NSCLC) (87% of cases) or small cell lung cancer (13% of cases) for the purpose of treatment \[[@R2]\]. Even with the recent advances in the treatment of lung cancers, the 5-year relative survival rate is currently 18%, as more than 50% of cases are diagnosed at an advanced stage \[[@R1]\].

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (TK). EGFR mutations lead to constitutive activation of downstream signaling pathways that promote cell proliferation \[[@R3]\]. EGFR mutations are present in 10% of NSCLC cases in North America and Europe, and more common (\> 50%) among non-smokers, adenocarcinomas, and Asian patients \[[@R4]\]. The most commonly found mutations are in-frame deletions of amino acids 747--750 in exon 19 (exon 19 deletion), accounting for 45% of mutations, and exon 21 mutations resulting in the single-point substitution mutation L858R, which accounts for 40%--45% of such mutations \[[@R4]\]. Both exon 19 deletions and the L858R point mutation result in activation of the TK domain, and both are correlated with sensitivity to small molecule TK inhibitors (TKIs), such as erlotinib, gefitinib, and afatinib. Treatment with TKIs is correlated with a statistically significant and clinically meaningful response rate and prognosis \[[@R5]\]. Among wild-type EGFR patients, survival was superior in those who received first-line chemotherapy than those who received erlotinib first followed by subsequent chemotherapy (11.6 vs. 8.7 months, respectively), while the point mutation T790M in exon 20 is associated with poorer response and shorter survival \[[@R6], [@R7]\]. Thus, detection of EGFR mutation status is critical to determine an appropriate treatment strategy, especially for the administration of EGFR-TKIs as a first-line therapy. Additional studies have shown that different mutations are associated with varying clinical outcomes. For example, NSCLC harboring the EGFR exon 19 deletion may be more susceptible to TKIs as compared with tumors with the L858R mutation \[[@R8]--[@R10]\]. So, detection of EGFR mutation type is important to predict the effect of TKI treatment.

Currently, tumor tissue, which is usually obtained by biopsy or surgery, is the gold standard for detection of EGFR mutations. Unfortunately, most NSCLC patients are diagnosed at an advanced stage; thus, it is difficult to obtain tumor samples from non-operated patients. Additionally, sample preservation and tumor heterogeneity also hamper the use of tumor tissue for cancer sequencing, with different areas of the same tumor showing different genetic profiles (intratumor heterogeneity) \[[@R11]\]. So, genomic analysis from single tumor biopsy may underestimate the mutational burden of heterogeneous tumors \[[@R12]\]. Thus, development of new methods is needed for the detection of EGFR mutations in patients with little or no available tumor sample.

Circulating cell-free DNA (cfDNA) can provide the same genetic information as a tissue biopsy and can be drawn at any time during the course of therapy allowing for dynamic monitoring of molecular change \[[@R11]\]. Detection of EGFR mutations in blood may provide a noninvasive and replicable source of genetic information \[[@R11], [@R13]\]. Although, numerous studies have investigated the diagnostic accuracy of cfDNA for detection of EGFR mutations \[[@R14]--[@R17]\], the concordance rate of EGFR mutations between cfDNA and tumor tissue varies.

Therefore, we conducted this meta-analysis to investigate the diagnostic accuracy of cfDNA for detection of the two main EGFR mutations in tumor tissues in lung cancer.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

Of a total of 313 articles identified during the initial search, 244 were excluded after reviewing the titles and abstracts, leaving 69 articles for further analysis of the full text. Of these, 27 articles met the inclusion criteria, which included 22 studies of all EGFR mutations \[[@R14]--[@R16], [@R18]--[@R35]\]. Eleven articles were selected for the meta-analysis of the exon 19 deletion and the L858R point mutation \[[@R14]--[@R17], [@R20], [@R28], [@R36]--[@R39]\] (Figure [1](#F1){ref-type="fig"}). Of these, Li et al. \[[@R20]\] detected EGFR mutations both in plasma and serum, so the data from plasma and serum were analyzed independently. All included studies were published between 2007 and 2015. Three studies were conducted in Japan \[[@R14], [@R28], [@R33]\], two in Korea \[[@R23], [@R27]\], two in France \[[@R16], [@R36]\], one in Australia \[[@R31]\], one in the US \[[@R35]\], one in Spain \[[@R39]\], one in Denmark \[[@R19]\], and the others in China. Characteristics of the eligible studies are shown in Table [1](#T1){ref-type="table"}.

![Flowchart of study selection](oncotarget-07-29154-g001){#F1}

###### Characteristics of eligible studies

  Author          Year   Country     Number   Female   Age          Ever smoker   AC    Method            Sample   TNM (I/II/III/IV/other)   All EGFR mutations   Exon 19 deletion   L858R point mutation                                            
  --------------- ------ ----------- -------- -------- ------------ ------------- ----- ----------------- -------- ------------------------- -------------------- ------------------ ---------------------- ----- ---- --- ---- ----- ---- ---- ---- -----
  Lam D           2015   China       74       36       65 ± 12      25            72    PNA-LNA PCR       plasma   0/0/4/70                  34                   1                  9                      30                                       
  Uchida J        2015   Japan       288      119      \< 60 (66)   NR            274   Deep sequencing   plasma   64/19/53/146/6            56                   22                 47                     163   27   5   26   230   26   14   26   222
  Karachaliou N   2015   Spain       97       68       \< 65 (45)   26            93    PNA clamp         serum    0/0/4/93                                                                                       47   0   9    41    29   0    12   56
  Mok T           2015   China       238      NR       NR           NR            NR    AS-PCR            plasma   NR                        72                   5                  24                     137   47   3   10   178   23   2    14   199
  Zhu G           2015   China       86       30       55 (28-81)   47            85    ddPCR             plasma   0/0/4/82                                                                                       18   1   4    63    12   3    3    68
  Douillard J     2014   France      652      NR       NR           NR            NR    ARMS              plasma   NR                        69                   1                  36                     546   48   0   23   581   21   1    13   617
  Couraud S       2014   France      59       NR       NR           NR            NR    NGS               plasma   NR                                                                                             11   2   9    37    6    0    2    53
  Weber B         2014   Denmark     196      NR       NR           NR            NR    AS-PCR            plasma   NR                        17                   6                  11                     162                                      
  Li X (plasma)   2014   China       121      NR       NR           NR            NR    ARMS              plasma   NR                        27                   3                  29                     62    17   2   16   86    11   2    12   97
  Li X (serum)    2014   China       92       NR       NR           NR            NR    ARMS              serum    NR                        19                   2                  29                     42    12   1   15   64    7    1    14   70
  Wang S          2014   China       134      65       \< 60 (90)   62            108   ARMS              plasma   0/0/19/115                15                   2                  53                     64                                       
  Jing C          2013   China       120      51       62 (36-85)   NR            70    HRM               plasma   38 (I/II)/ 82 (III/IV)    29                   2                  16                     73                                       
  Kim HR          2013   Korea       40       NR       NR           NR            NR    PNA               plasma   NR                        6                    0                  29                     5                                        
  Kim ST          2013   Korea       57       22       64 (28-84)   32            40    PNA-LNA PCR       serum    NR                        8                    3                  4                      42                                       
  Zhang H         2013   China       86       37       58 (21-80)   44            65    MEL               plasma   0/0/16/70                                                                                      15   0   7    64    8    0    6    72
  Liu X           2013   China       86       30       55 (28-81)   47            85    ARMS              plasma   0/0/4/82                  27                   0                  13                     46                                       
  Hu C            2012   China       47       NR       NR           NR            28    HRM               serum    NR                        22                   0                  2                      23                                       
  Zhao X          2012   China       111      35       \< 60 (52)   57            73    ME-PCR            plasma   22/10/33/46               16                   3                  29                     63                                       
  Goto K          2012   Japan       86       NR       NR           NR            NR    ARMS              serum    NR                        22                   0                  29                     35    11   0   18   57    10   0    12   64
  Xu F            2012   China       34       NR       NR           NR            NR    ARMS              serum    NR                                                                                             3    4   4    23    4    0    4    26
  Huang Z         2012   China       822      384      ≤ 65 (519)   340           641   DHPLC             plasma   NR                        188                  81                 108                    445                                      
  Jiang B         2011   China       58       18       56 (43-80)   36            42    ME-sequencing     serum    NR                        14                   0                  4                      40                                       
  Sriram K        2011   Australia   64       NR       NR           NR            NR    ME-PCR            serum    NR                        3                    0                  3                      58                                       
  He C            2009   China       18       NR       NR           NR            NR    ME-PCR            plasma   NR                        8                    1                  0                      9                                        
  Bai H           2009   China       230      107      60.7 ± 4.5   103           171   DHPLC             plasma   0/0/80/150                63                   16                 14                     137                                      
  Kuang Y         2009   USA         NR       NR       NR           NR            NR    ARMS              plasma   NR                        21                   2                  9                      11                                       
  Kimura H        2007   Japan       42       14       58 (40-81)   28            31    ARMS              serum    NR                        6                    1                  2                      33                                       

PCR: polymerase chain reaction; PNA-LNA PCR: peptide nucleic acid-locked nucleic acid PCR; AS-PCR: allele-specific PCR; ARMS: scorpion amplification refractory mutation system; HRM: high resolution melting; ddPCR: droplet digital PCR; PNA: peptide nucleic acid-mediated PCR clamping; MEL: mutant-enriched liquidchip; ME-PCR: mutant-enriched PCR; DHPLC: denaturing high-performance liquid chromatography; ME sequencing: mutant-enriched sequencing; NGS: next-generation sequencing; NR: not reported; AC: adenocarcinoma; TNM: tumor node metastasis;

TP: true positive; FP: false positive; FN: false negative; TN: true negative.

Quality assessment of studies {#s2_2}
-----------------------------

QUADAS-2 was used to estimate the quality of each eligible study. As shown in Table [2](#T2){ref-type="table"}, the methodological quality of the eligible studies was not significantly high.

###### Quality assessment of 27 studies by QUADAS-2

  Study           Risk of bias   Applicability concerns                    
  --------------- -------------- ------------------------ ---- --- --- --- ---
  Lam D           L              UC                       L    L   L   L   L
  Uchida J        L              L                        L    L   L   L   L
  Karachaliou N   L              L                        L    L   L   L   L
  Mok T           L              UC                       L    L   L   L   L
  Zhu G           L              H                        L    L   L   L   L
  Douillard J     L              L                        L    L   L   L   L
  Couraud S       L              L                        L    L   L   L   L
  Weber B         L              UC                       L    L   L   L   L
  Li X (plasma)   L              L                        L    L   L   L   L
  Li X (serum)    L              L                        L    L   L   L   L
  Wang S          L              UC                       L    L   L   L   L
  Jing C          L              L                        L    L   L   L   L
  Kim HR          L              L                        L    L   L   L   L
  Kim ST          L              L                        L    L   L   L   L
  Zhang H         L              L                        UC   L   L   L   L
  Liu X           L              L                        L    L   L   L   L
  Hu C            L              L                        UC   L   L   L   L
  Zhao X          L              L                        UC   L   L   L   L
  Goto K          L              L                        UC   L   L   L   L
  Xu F            L              L                        L    L   L   L   L
  Huang Z         L              UC                       L    L   L   L   L
  Jiang B         L              L                        L    L   L   L   L
  Sriram K        L              H                        L    L   L   L   L
  He C            L              H                        L    L   L   L   L
  Bai H           L              L                        L    L   L   L   L
  Kuang Y         L              UC                       L    L   L   L   L
  Kimura H        L              H                        L    L   L   L   L

L: Low H: High UC: Unclear.

Publication bias and sensitivity analysis {#s2_3}
-----------------------------------------

Deek\'s funnel plots and *p* values were used to estimate publication bias. As shown in Figure [2](#F2){ref-type="fig"}, the *p* values for all mutations and the L858R point mutation were 0.46 and 0.86, suggesting no significant publication bias, while the *p* value of the exon 19 deletion was 0.03, indicating the likelihood of publication bias. Thus, we conducted sensitivity analysis and found that the pooled results were not affected by individual studies (Figure [2](#F2){ref-type="fig"}).

![Deek\'s funnel plots and sensitivity analyses of all EGFR mutations (A, B), the exon 19 deletion (C, D), and the L858R point mutation (E, F) in the pooled studies](oncotarget-07-29154-g002){#F2}

Overall analysis {#s2_4}
----------------

Compared with NSCLC tumor tissues, the pooled sensitivity and specificity of cfDNA for the detection of EGFR mutation status were 0.60 (95% confidence intervals (95% CI) = 0.57--0.62) and 0.94 (95% CI = 0.93--0.95), respectively. The pooled sensitivity and specificity were 0.64 (95% CI = 0.60--0.69) and 0.99 (95% CI = 0.98--0.99) for detection of the exon 19 deletion, and 0.57 (95% CI = 0.51--0.63) and 0.99 (95% CI = 0.98--0.99) for detection of the L858R point mutation (Figure [3](#F3){ref-type="fig"}). positive likelihood ratio (PLR) and negative likelihood ratio (NLR) of cfDNA were 12.02 (95% CI = 7.71--18.74) and 0.41 (95% CI = 0.33--0.51) for detection of all mutations, 29.16 (95% CI = 12.82--66.29) and 0.39 (95% CI = 0.29--0.51) for detection of the exon 19 deletion, and 36.87 (95% CI = 16.17--84.09) and 0.44 (95% CI = 0.38--0.50) for detection of the L858R point mutation (Table [3](#T3){ref-type="table"}). The summary receiver operating characteristic (SROC) curves showed that the areas under the curve (AUC) of cfDNA for detection of all EGFR mutations, the exon 19 deletion, and the L858R point mutation were 0.9208, 0.9583, and 0.9605, respectively (Figure [4](#F4){ref-type="fig"}).

![Forest plots of sensitivity and specificity of cfDNA for detection of all EGFR mutations (A, B), the exon 19 deletion (C, D), and the L858R point mutation (E, F)](oncotarget-07-29154-g003){#F3}

###### Subgroup analysis

                         Study   Sensitivity         Specificity         PLR                      NLR                 DOR                       AUC
  ---------------------- ------- ------------------- ------------------- ------------------------ ------------------- ------------------------- --------
  **Mutation**                                                                                                                                  
  All EGFR mutations     22      0.60 (0.57--0.62)   0.94 (0.93--0.95)   12.02 (7.71--18.74)      0.41 (0.33--0.51)   34.36 (19.75--59.76)      0.9208
  Exon 19 deletion       11      0.64 (0.60--0.69)   0.99 (0.98--0.99)   29.16 (12.82--66.29)     0.39 (0.29--0.51)   84.74 (33.27 -- 215.88)   0.9583
  L858R point mutation   11      0.57 (0.51--0.63)   0.99 (0.98--0.99)   36.87 (16.17 -- 84.09)   0.44 (0.38--0.50)   91.28 (37.51--222.10)     0.9605
  **Blood type**                                                                                                                                
  Plasma                 15      0.60 (0.57--0.63)   0.93 (0.92--0.94)   10.45 (6.37--17.14)      0.42 (0.32--0.54)   29.36 (15.60--55.26)      0.9146
  Serum                  7       0.56 (0.48--0.64)   0.98 (0.95--0.99)   20.37 (9.45--43.91)      0.40 (0.26--0.60)   45.42 (18.99--108.62)     0.9347
  **Country**                                                                                                                                   
  China                  13      0.62(0.58--0.65)    0.91 (0.89--0.92)   11.19 (6.52--19.21)      0.37 (0.27--0.51)   34.55 (17.14--69.66)      0.9211
  Japan                  3       0.52 (0.44--0.60)   0.91 (0.87--0.94)   10.67 (2.40- 47.35)      0.51 (0.43--0.61)   24.23 (4.33--135.56)      0.8999
  Korea                  2       0.30 (0.17--0.45)   0.94 (0.83--0.99)   6.83 (2.40--19.45)       0.58 (0.13--2.63)   11.27 (1.03--123.54)      
  Other                  4       0.65 (0.57--0.72)   0.99 (0.98--0.99)   30.35 (4.84--190.29)     0.36 (0.30--0.45)   81.12 (12.05--546.05)     0.9569
  **Sample size**                                                                                                                               
  ≥ 90                   11      0.59 (0.56--0.62)   0.93 (0.92--0.94)   10.73 (6.29--18.29)      0.45 (0.34--0.59)   26.41 (13.65--51.08)      0.9054
  \< 90                  11      0.62 (0.56--0.68)   0.98 (0.95--0.99)   17.42 (9.64--31.50)      0.34 (0.22--0.54)   53.88 (24.63--117.84)     0.9422
  **Detection method**                                                                                                                          
  PNA-LNA PCR clamp      2       0.76 (0.63--0.87)   0.95 (0.87--0.99)   16.95 (5.07--56.73)      0.26 (0.16--0.42)   59.25 (16.49--212.84)     
  AS-PCR                 2       0.72 (0.63--0.79)   0.96 (0.94--0.98)   20.02 (10.24--39.11)     0.32 (0.20--0.49)   65.99 (31.49--138.31)     
  ARMS                   8       0.51 (0.46--0.56)   0.99 (0.98--0.99)   17.80 (6.58--48.21)      0.48 (0.35--0.67)   40.39 (12.81--127.34)     0.9291
  HRM                    2       0.74 (0.62--0.84)   0.98 (0.93--1.00)   29.00 (8.14--103.26)     0.22 (0.06--0.79)   97.31 (25.78--367.40)     
  ME-PCR                 3       0.46 (0.33--0.59)   0.97 (0.93--0.99)   8.91 (3.81--20.85)       0.53 (0.27--1.05)   19.13 (6.50--56.33)       0.9111
  DHPLC                  2       0.67 (0.62--0.72)   0.86 (0.83--0.88)   5.48 (2.93--10.24)       0.31 (0.14--0.65)   18.34 (4.69--71.64)       

![SROC curves of cfDNA for detection of all EGFR mutations (A), the exon 19 deletion (B), and the L858R point mutation (C)](oncotarget-07-29154-g004){#F4}

Threshold effect and heterogeneity {#s2_5}
----------------------------------

Spearman correlation coefficients and *p* values were calculated to assess the threshold effect using Meta-DiSc meta-analysis software \[[@R40]\]. The Spearman correlation coefficients for all EGFR mutations, the exon 19 deletion, and the L858R point mutation were −0.018, −0.255, and −0.055, respectively, and the *p* values were 0.938, 0.450, and 0.873, respectively, indicating that the threshold effect was not significant. As shown in Figure [3](#F3){ref-type="fig"}, the heterogeneity caused by the non-threshold effect was high, so we conducted meta-regression analysis to detect the source of heterogeneity. However, the results showed that the country, study size, detection method, and blood type did not contribute to heterogeneity (Table [4](#T4){ref-type="table"}).

###### Meta-regression with the covariates

  Covariates   All EGFR mutations   Exon 19 deletion   L858R point mutation                                                                                                         
  ------------ -------------------- ------------------ ---------------------- ------ ----------- -------- -------- -------- ------ -------------- -------- -------- -------- ------ ---------------
  Country      0.005                0.2880             0.9852                 1.01   0.55-1.85   0.151    0.6364   0.8217   1.16   0.23 -- 5.97   0.376    0.4240   0.4158   1.46   0.49 - 4.33
  Bloos type   0.182                0.8601             0.8354                 1.2    0.19-7.43   −1.387   1.2545   0.3191   0.25   0.01 -- 6.28   −1.297   0.9576   0.2335   0.27   0.02 -- 3.20
  Size         −0.753               0.7923             0.3560                 0.47   0.09-2.53   −0.918   1.2378   0.4915   0.40   0.02 -- 9.62   0.912    0.9504   0.3811   2.49   0.22 -- 28.66
  Method       0.011                0.1443             0.9414                 1.01   0.74-1.37   0.268    0.4298   0.5592   1.31   0.43 -- 3.95   0.232    0.3021   0.4774   1.26   0.58 -- 2.74

EGFR: epidermal growth factor receptor; 95 % CI: 95 % confidence interval; RDOR: relative diagnostic odds ratios

DISCUSSION {#s3}
==========

Although tumor tissue is the gold standard for detection of EGFR mutation status, major barriers exist in terms of acquisition and utility. To overcome the limitations of tissue biopsies, cfDNA can, in principle, provide the same genetic information as a tissue biopsy \[[@R11]\]. A number of studies have investigated the use of cfDNA for detection of the EGFR mutation status with varying results. Here, we performed a meta-analysis to evaluate the diagnostic accuracy of cfDNA for detection of EGFR mutations.

The pooled sensitivity and specificity of cfDNA for detection of EGFR mutations were 0.60 and 0.94, respectively. Several studies reported that differences in clinical outcomes were associated with different mutations. Lung cancer patients harboring the EGFR exon 19 deletion achieve longer survival following treatment with gefitinib or erlotinib, as compared to those with tumors harboring the L858R point mutation \[[@R8]--[@R10]\]. Additionally, the median overall survival (mOS) was shorter in patients with the L858R point mutation by cfDNA analysis than in those with the exon 19 deletion (13.7 vs. 30.0 months, respectively, *p* \< 0.01) \[[@R39]\]. So, we also estimated the diagnostic accuracy of cfDNA for detection of the exon 19 deletion and the L858R point mutation. Our result showed that the pooled sensitivities of cfDNA for detection of the exon 19 deletion and the L858R point mutation were 0.64 and 0.57, and the pooled specificity were 0.99 and 0.99, respectively, indicating that cfDNA had a high degree of specificity, likely because mutations found in cfDNA are, in essence, integral agents of tumors that are defined by their presence in tumor DNA and absence in matched normal DNA \[[@R11]\].

cfDNA analysis is a noninvasive technique to predict patient response to EGFR-TKI treatment, dynamically assess treatment outcome, and facilitate early detection of resistance mutations. Que D et al. \[[@R41]\] reported that EGFR-TKI treatment significantly improved mOS in patients harboring the EGFR mutation in cfDNA than those that did not exhibit EGFR mutation (25.7 vs 13.5 months, respectively). Additionally, for EGFR mutations at baseline patients, Lee et al. \[[@R42]\] reported that the mOS was improved among patient with undetectable EGFR, as compared to detectable EGFR mutations in cfDNA (23.7 vs. 11.2 months) after TKI treatment for 2 months, in accordance with the findings of Mok et al. \[[@R15]\] who reported that the mOS for patients who continued to have detectable EGFR mutations at cycle 3 was 18.2 months and 31.9 months for patients without detectable mutations. The T790M point mutation is associated with acquired resistance to TKI therapy and reportedly occurs in about 50% of patients with disease progression after initial response to gefitinib or erlotinib \[[@R35]\]. As cfDNA had a high specificity to detect EGFR mutations, cfDNA might be a suitable noninvasive screening test to monitor T790M mutations during TKI treatment \[[@R35]\]. Lee et al. \[[@R42]\] found that 14 (28.6%) of 49 patients harbored the resistance mutation T790M in cfDNA during EGFR TKIs treatment, which is similar to the studies by Sakai et al. \[[@R43]\] and Sorensen et al. \[[@R44]\], in which the T790M mutation was detected in 21 (30%) of 75 and 9 (39%) of 23 blood samples from patients with clinical progressive disease. Most interestingly, several studies demonstrated that monitoring the EGFR mutations in cfDNA allows for the detection of the T790M mutation up to 344 days (range, 15--344 days) before radiographic documentation of disease progression \[[@R42], [@R44]\]. Additionally, Patients whose EGFR mutations switched from positive to negative after chemotherapy achieved a better partial response than patients with a reversal in mutation status \[[@R45]\], indicating that the high specificity of cfDNA could serve as an effective test to estimate the effect of chemotherapy.

The AUC is an established global measure of performance of diagnostic tests. According to the criteria, 0.9 \< AUC \< 1 indicates high diagnostic accuracy \[[@R46]\]. Our result showed that the AUCs of all EGFR mutations, the exon 19 deletion, and the L858R point mutation were 0.9208, 0.9583, and 0.9605, respectively, indicating high diagnostic accuracy of cfDNA. Likelihood ratios are alternative statistical parameters to summarize diagnostic accuracy and values \> 10 and \< 0.1 are considered to provide strong evidence to rule in or rule out diagnoses, respectively \[[@R47]\]. In the present study, the PLR was \> 10, indicating that cfDNA accurately confirmed the presences of EGFR mutations (Table [3](#T3){ref-type="table"}). Diagnostic odds ratio (DOR) is a single indicator of test performance that combines the strengths of sensitivity and specificity with the advantage of accuracy. The value of a DOR ranges from 0 to infinity, with higher values indicating better discriminatory test performance \[[@R48]\]. Our results showed that cfDNA had high diagnostic performance with DORs of 34.36, 84.74 and 91.28 for detection of all EGFR mutations, the exon 19 deletion, and the L858R point mutation. We used Spearman correlation coefficients and *p* values to assess the threshold effect, which is a major source of intra-study heterogeneity. The *p* values for all EGFR mutations, the exon 19 deletion, and the L858R point mutation were 0.938, 0.450, and 0.873, respectively, indicating that the threshold effect was not significant. Thus, meta-regression analysis was performed to detect the source of heterogeneity, but, unfortunately, none of the analyzed covariates was found to be the source of heterogeneity (Table [4](#T4){ref-type="table"}).

Various methods can be used to detect EGFR mutations in cfDNA, such us allele-specific PCR (AS-PCR) \[[@R15]\], peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA-PCR) \[[@R18]\], amplification refractory mutation system (ARMS) \[[@R20]\], high resolution melting (HRM) \[[@R22]\], mutant-enriched (ME)-PCR \[[@R26]\], and denaturing high-performance liquid chromatography (DHPLC) \[[@R29]\]. Our results showed that the sensitivities of PNA-LNA PCR, AS-PCR, and HRM were higher than those of ARMS and ME-PCR, but the specificity of ARMS was the highest among the other tests. Analysis of methods for detection of EGFR mutations in plasma demonstrated that ARMS had highest specificity, as compared with the other methods \[[@R38]\]. Although cfDNA can be extracted from either plasma or serum, our results showed that cfDNA extracted from serum had higher diagnostic accuracy than that extracted from plasma (Table [3](#T3){ref-type="table"}).

There were some limitations to this study that should be addressed. First, chemotherapy can change the EGFR status \[[@R45]\], which could lead to analytical inconsistencies between tissues and cfDNA in blood collected after treatment. Second, although we accessed the threshold effect and performed meta-regression analysis, high heterogeneity was detected, but none of the analyzed factors was found to be the source of the heterogeneity. Therefore, other factors, such as sex, smoking status, or tumor size may have been the cause of the observed heterogeneity. Third, publication bias was detected when the performance of cfDNA to detect the exon 19 deletion was analyzed; therefore, we conducted sensitivity analysis and found that the pooled results were not affected by the inclusion of individual studies.

In conclusion, cfDNA offers an effective and noninvasive method to detect EGFR mutation status in NSCLC. Due to its high specificity and noninvasive characteristics, cfDNA analysis presents a promising method to screen for mutations in NSCLC and predict patient response to EGFR-TKI treatment, dynamically assess treatment outcome, and facilitate early detection of resistance mutations.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

A comprehensive search of the PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) and Google Scholar (<http://www.scholar.google.com/>) databases using the keywords "cell free DNA OR circulating DNA OR circulating tumor DNA OR serum DNA OR plasma DNA" AND "lung cancer OR non-small cell lung cancer" AND "EGFR OR Epidermal Growth Factor Receptor OR erbB1" was conducted to identify relevant studies published before September 28, 2015. In addition, the references from the retrieved articles that matched our inclusion criteria were manually searched.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The inclusion criteria for studies were as follows: (a) a histopathological diagnosis of NSCLC; (b) matched tissue and cfDNA sample; (c) identification of EGFR mutation status both in tissue and cfDNA; (d) sufficient data to construct a diagnostic 2 × 2 table; and (e) enrollment of at least 15 patients. Studies were excluded if they were: (a) not written in English; (b) tumor tissue and blood samples were not paired; or (c) case reports or reviews. Two of the authors (X.Q. and J.L.) read the titles and abstracts independently, and excluded studies that did not meet the inclusion criteria. Then, the full texts were screened to determine if they met the inclusion criteria.

Data extraction {#s4_3}
---------------

Two independent reviewers (YH.S. and MF.W.) assessed the articles. The name of the first author, year of publication, country, histologic type, tumor stage, distribution of age and sex, techniques used for EGFR mutation detection in cfDNA, serum or plasma, and true positive (TP), false positive (FP), false negative (FN), and true negative (TN) rates were collected from eligible studies. When EGFR mutations were detected by multiple methods, the method with the best sensitivity or specificity was extracted.

Quality assessment {#s4_4}
------------------

Quality assessment of diagnostic accuracy studies 2 (QUADAS-2) is a revised tool for the quality assessment of diagnostic accuracy studies \[[@R49]\]. The QUADAS-2 comprises four domains: patient selection, index test, reference standard, and flow and timing. Signaling questions are included to help judge risk of bias as "low," "high," or "unclear."

Statistical analysis {#s4_5}
--------------------

The threshold effect was estimated with Meta-DiSc meta-analysis software \[[@R40]\]. A probability (*p*) value \< 0.05 was considered to reflect a significant threshold effect. Heterogeneity due to a non-threshold effect was determined using the *Q* test and the inconsistency index (*I*^2^) test with *p* ≤ 0.05 and *I*^2^ ≥ 50% indicating significant heterogeneity. Meta-regression analysis was conducted to detect the source of heterogeneity. According to the heterogeneity test results, a random or fixed model was used to pool the sensitivity/specificity rates, PLR, NLR, DOR, and corresponding 95% CI. SROC and AUC were also calculated. Publication bias and sensitivity analyses were performed using STATA software (version 11.0; StataCorp LP, College Station, TX, USA), while all other analyses were performed using Meta-DiSc (version 1.4) meta-analysis software \[[@R40]\].
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